Document is current

Any future updates will be listed below

Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study

Crossref DOI link: https://doi.org/10.1186/s12933-020-01060-1

Published Online: 2020-06-22

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark